Insights into the antigenic advancement of influenza A(H3N2) viruses, 2011–2018

Scientific Reports

Volumn 9, Issue 1, 2019, Pages

  Jorquera, Patricia A ^a,b   Mishin, Vasiliy P ^a   Chesnokov, Anton ^a   Nguyen, Ha T ^a,c   Mann, Brian ^a,c   Garten, Rebecca ^a   Barnes, John ^a   Hodges, Erin ^a,b   De La Cruz, Juan ^a,c   Xu, Xiyan ^a   Katz, Jackie ^a   Wentworth, David E ^a   Gubareva, Larisa V ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CNI Advantage   (United States)

^c BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANIMAL; CLASSIFICATION; GENETICS; GLYCOSYLATION; HEMAGGLUTINATION INHIBITION TEST; HUMAN; IMMUNOLOGY; INFLUENZA; INFLUENZA A VIRUS (H3N2); METABOLISM; MUSTELA PUTORIUS FURO; PHYLOGENY; PHYSIOLOGY; PROCEDURES; SERODIAGNOSIS; VIROLOGY;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; FERRETS; GLYCOSYLATION; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNE SERA; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEUTRALIZATION TESTS; PHYLOGENY;

EID: 85060869948     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-019-39276-1     Document Type: Article

References (40)

1. Doud, M. B., Hensley, S. E. & Bloom, J. D. Complete mapping of viral escape from neutralizing antibodies. PLoS Pathog 13(3), e1006271 (2017).
2. Garten, R. et al. Update: Influenza Activity in the United States During the 2017–18 Season and Composition of the 2018–19 Influenza Vaccine. MMWR Morb Mortal Wkly Rep 67(22), 634–642 (2018).
3. Bedford, T. N. R. Seasonal influenza circulation patterns and projections for Feb 2018 to Feb 2019. bioRxiv (2018).
4. WHO. Worldwide Influenza Centre- The Francis Crick Instititute. February 2017 Interim Report. Available from, https://www.crick.ac.uk/sites/default/files/2018-07/crick_sh2017_vcm_report_to_post.pdf (2017).
5. Smith, D. J. et al. Mapping the antigenic and genetic evolution of influenza virus. Science 305(5682), 371–6 (2004).
6. Group, W. H. O. W. et al. Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14–16 June 2010. Influenza Other Respir Viruses, 6(2): 142–52, e1-5 (2012).
7. Barr, I. G. et al. WHO recommendations for the viruses used in the 2013–2014 Northern Hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013. Vaccine 32(37), 4713–25 (2014).
8. Klimov, A. I. et al. WHO recommendations for the viruses to be used in the 2012 Southern Hemisphere Influenza Vaccine: epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from February to September 2011. Vaccine 30(45), 6461–71 (2012).
9. Buckland, B. C. The development and manufacture of influenza vaccines. Hum Vaccin Immunother 11(6), 1357–60 (2015).
10. Zost, S. J. et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci USA 114(47), 12578–12583 (2017).
11. Lin, Y. et al. The characteristics and antigenic properties of recently emerged subclade 3C.3a and 3C.2a human influenza A(H3N2) viruses passaged in MDCK cells. Influenza Other Respir Viruses 11(3), 263–274 (2017).
12. Chambers, B. S. et al. Identification of Hemagglutinin Residues Responsible for H3N2 Antigenic Drift during the 2014–2015 Influenza Season. Cell Rep 12(1), 1–6 (2015).
13. Flannery, B. et al. Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014–2015. J Infect Dis 214(7), 1010–9 (2016).
14. Petrie, J. G. et al. The Household Influenza Vaccine Effectiveness Study: Lack of Antibody Response and Protection Following Receipt of 2014–2015 Influenza Vaccine. Clin Infect Dis 65(10), 1644–1651 (2017).
15. Redlberger-Fritz, M., Kundi, M. & Popow-Kraupp, T. Detailed Report on 2014/15 Influenza Virus Characteristics, and Estimates on Influenza Virus Vaccine Effectiveness from Austria’s Sentinel Physician Surveillance Network. PLoS One 11(3), p. e0149916 (2016).
16. Pereyaslov, D. et al. Improving the representativeness of influenza viruses shared within the WHO Global Influenza Surveillance and Response System. Influenza Other Respir Viruses 10(2), 68–75 (2016).
17. Ampofo, W. K. et al. Strengthening the influenza vaccine virus selection and development process: Report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1–3 April 2014. Vaccine 33(36), 4368–82 (2015).
18. Lin, Y. et al. Optimisation of a micro-neutralisation assay and its application in antigenic characterisation of influenza viruses. Influenza Other Respir Viruses 9(6), 331–340 (2015).
19. WHO. Recommended composition of influenza virus vaccines for use in the 2018–2019 northern hemisphere influenza season. Available from, http://www.who.int/influenza/vaccines/virus/recommendations/2018_19_north/en/ (2018).
20. Wyrzucki, A. et al. Alternative recognition of the conserved stem epitope in influenza A virus hemagglutinin by a VH3-30-encoded heterosubtypic antibody. J Virol 88(12), 7083–92 (2014).
21. McWhite, C. D., Meyer, A. G. & Wilke, C. O. Sequence amplification via cell passaging creates spurious signals of positive adaptation in influenza virus H3N2 hemagglutinin. Virus Evol, 2016. 2(2).
22. Xie, H. et al. H3N2 Mismatch of 2014–15 Northern Hemisphere Influenza Vaccines and Head-to-head Comparison between Human and Ferret Antisera derived Antigenic Maps. Sci Rep 5, 15279 (2015).
23. WHO, Recommended composition of influenza virus vaccines for use in the 2016 southern hemisphere influenza season. Weekly epidemiological record, 90(41): 545–560 (2015).
24. WHO, Review of the 2014–2015 influenza season in the northern hemisphere. Weekly epidemiological record, 90(23): p. 281–296 (2015).
25. WHO. Worldwide Influenza Centre- The Francis Crick Instititute. Annual and Interim Reports.; Available from, https://www.crick.ac.uk/partnerships/worldwide-influenza-centre/annual-and-interim-reports.
26. Lin, Y. P. et al. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment? J Virol 84(13), 6769–81 (2010).
27. Tamura, D. et al. Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment. Antimicrob Agents Chemother 57(12), 6141–6 (2013).
28. WHO. Worldwide Influenza Centre- The Francis Crick Instititute. February 2015 Interim Report. 2015; Available from, https://www.crick.ac.uk/sites/default/files/2018-07/nimr-report-feb2015-web.pdf.
29. van Baalen, C. A. et al. ViroSpot microneutralization assay for antigenic characterization of human influenza viruses. Vaccine 35(1), 46–52 (2017).
30. WHO. Recommended composition of influenza virus vaccines for use in the 2015 southern hemisphere influenza season; Available from, http://www.who.int/influenza/vaccines/virus/recommendations/2015_south/en/ (2014).
31. Li, C. et al. Selection of antigenically advanced variants of seasonal influenza viruses. Nat Microbiol 1(6), 16058 (2016).
32. A*STAR Bioinformatics Institute (BII), S. FluSurver, [cited 2018 6/20/2018], http://flusurver.bii.a-star.edu.sg/ (2009).
33. Tusche, C., Steinbruck, L. & McHardy, A. C. Detecting patches of protein sites of influenza A viruses under positive selection. Mol Biol Evol 29(8), 2063–71 (2012).
34. Koel, B. F. et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science 342(6161), 976–9 (2013).
35. Iba, Y. et al. Conserved neutralizing epitope at globular head of hemagglutinin in H3N2 influenza viruses. J Virol 88(13), 7130–44 (2014).
36. Li, Y. et al. Single hemagglutinin mutations that alter both antigenicity and receptor binding avidity influence influenza virus antigenic clustering. J Virol 87(17), 9904–10 (2013).
37. Hurt, A. C., Okomo-Adhiambo, M. & Gubareva, L. V. The fluorescence neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors. Methods Mol Biol 865, 115–25 (2012).
38. Shepard, S. S. et al. Viral deep sequencing needs an adaptive approach: IRMA, the iterative refinement meta-assembler. BMC Genomics 17, 708 (2016).
39. Tamura, K. et al. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol 30(12), 2725–9 (2013).
40. Mishin, V. P. et al. A Pyrosequencing-Based Approach to High-Throughput Identification of Influenza A(H3N2) Virus Clades Harboring Antigenic Drift Variants. J Clin Microbiol 55(1), 145–154 (2017).